Molecular Partners Set to Present Posters at the 2024 SITC Annual Meeting

2 min read | October 04, 2024 06:12 AM PDT | By Team Kalkine Media

Google News:

Molecular Partners Set to Present Posters at the 2024 SITC Annual Meeting — Image source: Shutterstock

Recent News

Oracle's AI Push Gains Ground Across Critical Services

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Make Kalkine Media
My Trusted Source

Highlights:

Molecular Partners AG will present proof-of-concept data for its novel CD3 Switch-DARPin at the 2024 SITC Annual Meeting.
The company will also showcase additional analyses from the Phase 1 study of MP0317, focusing on advanced solid tumors.
Two poster presentations are scheduled for November 9, 2024, highlighting advancements in T cell engagement and tumor microenvironment modulation.

Molecular Partners AG {NASDAQ:MOLN} has announced its participation in the upcoming 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where it will present innovative research findings in the field of oncology. The company is set to introduce proof-of-concept data for its new CD3 Switch-DARPin, a novel therapeutic designed to address the challenges associated with T cell engagers in solid tumors. This advancement represents a significant step forward in enhancing the effectiveness of immunotherapy for patients with these difficult-to-treat cancers.

In addition to the CD3 Switch-DARPin data, Molecular Partners will provide further analyses from the Phase 1 study of MP0317, a FAP-localized CD40 agonistic DARPin. This research emphasizes the potential of MP0317 in modulating the tumor microenvironment in patients with advanced solid tumors, contributing to a deeper understanding of its therapeutic benefits.

Two poster presentations are scheduled for November 9, 2024, from 9 am to 8:30 pm CT in Exhibit Halls AB. The titles and details of the presentations include:

"Unlocking precision: a next generation multi-specific CD3 Switch-DARPin with enhanced function to tackle the current limitations of T cell engagers in ovarian cancer" (Abstract & Poster Number: 842)
"Comprehensive biomarker analyses from a Phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin" (Abstract & Poster Number: 612)

Following the conference, the posters will be made available on Molecular Partners' website, allowing broader access to the research findings. This initiative underscores the company’s commitment to advancing cancer treatments and contributing valuable insights into the immuno-oncology landscape. Molecular Partners continues to strive for innovation in therapeutic strategies, aiming to improve outcomes for patients facing solid tumors.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.